HilleVax Email Format
Biotechnology ResearchMassachusetts, United States51-200 Employees
HilleVax is a biotechnology research company based in Boston, Massachusetts, focused on developing and commercializing novel vaccines. Its initial program, HIL-214, is a virus-like particle–based vaccine candidate intended to prevent moderate-to-severe acute gastroenteritis caused by norovirus infection. The information presents the company as operating within the biopharmaceutical field to address infectious disease prevention through vaccine development. The material does not specify a defined customer base; the vaccine target is a health problem affecting individuals and healthcare systems. As a mid-sized organization in the biotechnology sector, HilleVax is positioned to advance its vaccine candidate in a field focused on preventing infectious gastroenteritis.